Andreas Halvorsen: portfolio of Viking Global Investors
Andreas Halvorsen leads Viking Global Investors, a hedge fund that analyzes stocks worldwide and combines long and short positions.
Source: 13F filing with the US Securities and Exchange Commission dated May 15, 2024. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included. Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary
You are looking at Q1 2024. Go to the latest filing (Q3 2026)
- Total value of stock positions
- 26.9B USD
- Positions
- 83
- Share of the ten largest
- 40.9%
The ten largest positions Q1 2024
- Visa Inc. 6.6%▲ +11.2%
- Workday, Inc. 5.4%▲ +28.8%
- Amazon 4.6%▲ +40.0%
- Philip Morris International 4.4%▲ +35.3%
- Api Group Corp 4.2%▼ −15.5%
- U.S. Bancorp 3.8%▲ +136.4%
- Las Vegas Sands 3.3%new
- Fortive 3.0%▼ −9.8%
- Bridgebio Pharma Inc 2.9%unchanged
- Roivant Sciences Ltd 2.7%unchanged
Show all positions of this quarter
Choose a quarter (54 filings)
- Q3 2026
- Q2 2026
- Q1 2026
- Q4 2025
- Q3 2025
- Q2 2025
- Q1 2025
- Q4 2024
- Q3 2024
- Q2 2024
- Q1 2024
- Q4 2023
- Q3 2023
- Q2 2023
- Q1 2023
- Q4 2022
- Q3 2022
- Q2 2022
- Q1 2022
- Q4 2021
- Q3 2021
- Q2 2021
- Q1 2021
- Q4 2020
- Q3 2020
- Q2 2020
- Q1 2020
- Q4 2019
- Q3 2019
- Q2 2019
- Q1 2019
- Q4 2018
- Q3 2018
- Q2 2018
- Q1 2018
- Q4 2017
- Q3 2017
- Q2 2017
- Q1 2017
- Q4 2016
- Q3 2016
- Q2 2016
- Q1 2016
- Q4 2015
- Q3 2015
- Q2 2015
- Q1 2015
- Q4 2014
- Q3 2014
- Q2 2014
- Q1 2014
- Q4 2013
- Q3 2013
- Q2 2013
All positions Q1 2024
| Symbol | Weight | Shares | Reported value | Change | Held since |
|---|---|---|---|---|---|
| V Visa Inc. | 6.6% | 6,327,962 | 1.8B USD | +11.2% increased | Q3 2016 31 quarters |
| WDAY Workday, Inc. | 5.4% | 5,288,586 | 1.4B USD | +28.8% increased | Q1 2023 5 quarters |
| AMZN Amazon | 4.6% | 6,902,351 | 1.2B USD | +40.0% increased | Q2 2015 36 quarters |
| PM Philip Morris International | 4.4% | 13,016,896 | 1.2B USD | +35.3% increased | Q2 2023 4 quarters |
| Api Group Corp | 4.2% | 28,984,298 | 1.1B USD | −15.5% reduced | Q2 2020 16 quarters |
| USB U.S. Bancorp | 3.8% | 22,626,465 | 1.0B USD | +136.4% increased | Q4 2023 2 quarters |
| LVS Las Vegas Sands | 3.3% | 16,923,581 | 874.9M USD | new | Q1 2024 1 quarter |
| FTV Fortive | 3.0% | 9,497,292 | 817.0M USD | −9.8% reduced | Q3 2019 19 quarters |
| Bridgebio Pharma Inc | 2.9% | 25,120,991 | 776.7M USD | unchanged | Q2 2019 20 quarters |
| Roivant Sciences Ltd | 2.7% | 69,368,961 | 731.1M USD | unchanged | Q4 2021 10 quarters |
| TMUS T-Mobile US | 2.7% | 4,381,297 | 715.1M USD | +190.2% increased | Q4 2023 2 quarters |
| AMD Advanced Micro Devices | 2.7% | 3,952,088 | 713.3M USD | −16.6% reduced | Q4 2023 2 quarters |
| AMP Ameriprise Financial | 2.7% | 1,626,845 | 713.3M USD | −15.0% reduced | Q1 2021 13 quarters |
| DHR Danaher Corporation | 2.6% | 2,837,937 | 708.7M USD | −29.1% reduced | Q2 2023 4 quarters |
| UNH UnitedHealth Group | 2.5% | 1,361,207 | 673.4M USD | +195.4% increased | Q3 2022 7 quarters |
| MSFT Microsoft | 2.5% | 1,596,887 | 671.8M USD | new | Q1 2024 1 quarter |
| AAPL Apple Inc. | 2.5% | 3,870,990 | 663.8M USD | new | Q1 2024 1 quarter |
| PGR Progressive Corporation | 2.3% | 3,032,941 | 627.3M USD | −48.3% reduced | Q1 2022 9 quarters |
| Biomarin Pharmaceutical Inc | 2.1% | 6,416,288 | 560.4M USD | +31.2% increased | Q4 2021 10 quarters |
| GE GE Aerospace | 1.8% | 2,731,787 | 479.5M USD | −46.3% reduced | Q4 2020 14 quarters |
| FCX Freeport-McMoRan | 1.7% | 9,517,164 | 447.5M USD | −13.9% reduced | Q3 2023 3 quarters |
| CBRE CBRE Group | 1.7% | 4,568,632 | 444.3M USD | +19.9% increased | Q2 2023 4 quarters |
| MA Mastercard | 1.4% | 794,313 | 382.5M USD | −31.4% reduced | Q1 2022 9 quarters |
| META Meta Platforms | 1.3% | 731,983 | 355.4M USD | −75.5% reduced | Q4 2020 14 quarters |
| Royalty Pharma PLC | 1.3% | 11,485,547 | 348.8M USD | +13.9% increased | Q2 2020 16 quarters |
| DLTR Dollar Tree | 1.3% | 2,571,820 | 342.4M USD | new | Q1 2024 1 quarter |
| TEAM Atlassian | 1.3% | 1,748,686 | 341.2M USD | +301.1% increased | Q4 2023 2 quarters |
| Hdfc Bank Ltd | 1.2% | 5,929,295 | 331.9M USD | −39.1% reduced | Q3 2021 11 quarters |
| MCK McKesson Corporation | 1.2% | 590,580 | 317.1M USD | −73.6% reduced | Q2 2022 8 quarters |
| ISRG Intuitive Surgical | 1.1% | 771,837 | 308.0M USD | −17.1% reduced | Q3 2023 3 quarters |
| Cboe Global Mkts Inc | 1.1% | 1,655,050 | 304.1M USD | −31.4% reduced | Q4 2023 2 quarters |
| TTWO Take-Two Interactive | 1.1% | 2,009,195 | 298.3M USD | −16.7% reduced | Q4 2023 2 quarters |
| ADBE Adobe Inc. | 1.1% | 562,548 | 283.9M USD | new | Q1 2024 1 quarter |
| Inhibrx Inc | 0.9% | 7,150,826 | 250.0M USD | unchanged | Q3 2020 15 quarters |
| FIVE9 Inc | 0.8% | 3,452,138 | 214.4M USD | +27.2% increased | Q2 2023 4 quarters |
| Acadia Healthcare Company In | 0.8% | 2,564,237 | 203.1M USD | −8.4% reduced | Q4 2020 14 quarters |
| Ferguson PLC New | 0.7% | 875,421 | 191.2M USD | new | Q1 2024 1 quarter |
| Newamsterdam Pharma Company | 0.7% | 8,024,565 | 189.8M USD | unchanged | Q4 2022 6 quarters |
| HCA HCA Healthcare | 0.7% | 529,401 | 176.6M USD | −27.0% reduced | Q4 2023 2 quarters |
| Ginkgo Bioworks Holdings Inc | 0.6% | 143,085,126 | 166.0M USD | unchanged | Q3 2021 11 quarters |
| Regal Rexnord Corporation | 0.6% | 900,529 | 162.2M USD | +30.2% increased | Q4 2023 2 quarters |
| HUM Humana | 0.6% | 464,130 | 160.9M USD | new | Q1 2024 1 quarter |
| Epam Sys Inc | 0.6% | 579,543 | 160.0M USD | +57.2% increased | Q2 2023 4 quarters |
| Standard Biotools Inc | 0.6% | 58,651,170 | 158.9M USD | new | Q1 2024 1 quarter |
| Cnh Indl N V | 0.6% | 11,956,128 | 155.0M USD | +21.3% increased | Q1 2023 5 quarters |
| CSX CSX Corporation | 0.5% | 3,957,797 | 146.7M USD | +26.3% increased | Q4 2022 6 quarters |
| KDP Keurig Dr Pepper | 0.5% | 4,461,076 | 136.8M USD | +54.5% increased | Q3 2023 3 quarters |
| Lamb Weston HLDGS Inc | 0.5% | 1,205,772 | 128.5M USD | −66.0% reduced | Q4 2023 2 quarters |
| BSX Boston Scientific | 0.4% | 1,724,755 | 118.1M USD | −23.9% reduced | Q3 2023 3 quarters |
| KKR KKR & Co. | 0.4% | 1,071,166 | 107.7M USD | −22.9% reduced | Q4 2023 2 quarters |
| Valvoline Inc | 0.4% | 2,383,579 | 106.2M USD | −25.0% reduced | Q3 2022 7 quarters |
| LLY Lilly (Eli) | 0.4% | 134,608 | 104.7M USD | −3.0% reduced | Q4 2023 2 quarters |
| CPT Camden Property Trust | 0.4% | 1,030,340 | 101.4M USD | new | Q1 2024 1 quarter |
| Adaptive Biotechnologies Cor | 0.4% | 29,993,708 | 96.3M USD | unchanged | Q2 2019 20 quarters |
| Knight-Swift Transn HLDGS In | 0.4% | 1,717,327 | 94.5M USD | new | Q1 2024 1 quarter |
| 4D Molecular Therapeutics In | 0.3% | 2,934,914 | 93.5M USD | −38.7% reduced | Q4 2020 14 quarters |
| Viking Therapeutics Inc | 0.3% | 1,094,940 | 89.8M USD | – | Q1 2023 5 quarters |
| PPG PPG Industries | 0.3% | 619,433 | 89.8M USD | −36.1% reduced | Q2 2023 4 quarters |
| Pharvaris N V | 0.3% | 3,653,310 | 84.4M USD | −0.1% reduced | Q1 2021 13 quarters |
| VRT Vertiv | 0.3% | 1,017,994 | 83.1M USD | new | Q1 2024 1 quarter |
| APD Air Products | 0.3% | 338,206 | 81.9M USD | new | Q1 2024 1 quarter |
| Procore Technologies Inc | 0.3% | 991,229 | 81.4M USD | +61.6% increased | Q4 2023 2 quarters |
| Equitable HLDGS Inc | 0.3% | 2,057,191 | 78.2M USD | new | Q1 2024 1 quarter |
| TMO Thermo Fisher Scientific | 0.3% | 128,489 | 74.7M USD | −76.1% reduced | Q2 2020 16 quarters |
| BEKE KE Holdings | 0.3% | 5,246,500 | 72.0M USD | −0.7% reduced | Q3 2023 3 quarters |
| OSCR Oscar Health | 0.3% | 4,732,002 | 70.4M USD | new | Q1 2024 1 quarter |
| CLX Clorox | 0.3% | 457,659 | 70.1M USD | new | Q1 2024 1 quarter |
| Skechers U S A Inc | 0.2% | 1,090,121 | 66.8M USD | new | Q1 2024 1 quarter |
| Edgewise Therapeutics Inc | 0.2% | 3,339,146 | 60.9M USD | – | Q1 2021 13 quarters |
| Immunovant Inc | 0.2% | 1,809,172 | 58.5M USD | new | Q1 2024 1 quarter |
| Oric Pharmaceuticals Inc | 0.2% | 4,000,000 | 55.0M USD | new | Q1 2024 1 quarter |
| Integer HLDGS Corp | 0.2% | 428,399 | 50.0M USD | new | Q1 2024 1 quarter |
| Day One Biopharmaceuticals I | 0.2% | 2,558,563 | 42.3M USD | unchanged | Q2 2021 12 quarters |
| Zai Lab Ltd | 0.1% | 2,048,129 | 32.8M USD | +9.6% increased | Q1 2021 13 quarters |
| WTW Willis Towers Watson | 0.1% | 112,344 | 30.9M USD | new | Q1 2024 1 quarter |
| Verastem Inc | 0.1% | 2,456,292 | 29.0M USD | unchanged | Q2 2023 4 quarters |
| Cazoo Group Ltd | < 0.1% | 2,142,728 | 25.7M USD | unchanged | Q4 2023 2 quarters |
| Pepgen Inc | < 0.1% | 1,482,434 | 21.8M USD | unchanged | Q2 2022 8 quarters |
| Longboard Pharmaceuticals In | < 0.1% | 981,328 | 21.2M USD | new | Q1 2024 1 quarter |
| Trevi Therapeutics Inc | < 0.1% | 4,400,000 | 15.2M USD | unchanged | Q3 2022 7 quarters |
| RDDT Reddit | < 0.1% | 225,000 | 11.1M USD | new | Q1 2024 1 quarter |
| Rallybio Corp | < 0.1% | 4,194,777 | 7.8M USD | unchanged | Q3 2021 11 quarters |
| Kinnate Biopharma Inc | < 0.1% | 1,820,462 | 4.8M USD | unchanged | Q4 2020 14 quarters |
“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.
Breakdown by sector
- Financials 17.3%
- Technology 14.1%
- Health Care 9.8%
- Consumer Discretionary 7.9%
- Consumer Staples 6.5%
- Industrials 5.7%
- Communication Services 5.1%
- Materials 2.3%
- Real Estate 2.0%
- not in our coverage 29.3%
Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.
How to read this page
- Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
- Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
- Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.
All superinvestor portfolios Screener: stocks held by superinvestors